The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma

The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma

The authors report the results of the phase II PEMDAC clinical study testing the combination of the HDAC inhibitor entinostat with the anti- PD-1 antibody pembrolizumab in uveal melanoma. Low tumor burden, a wildtype BAP1 gene in the tumor or iris melanoma correlates with response and longer surviva...

Full description

Bibliographic Details
Main Authors: Lars Ny, Henrik Jespersen, Joakim Karlsson, Samuel Alsén, Stefan Filges, Charlotta All-Eriksson, Bengt Andersson, Ana Carneiro, Hildur Helgadottir, Max Levin, Ingrid Ljuslinder, Roger Olofsson Bagge, Vasu R. Sah, Ulrika Stierner, Anders Ståhlberg, Gustav Ullenhag, Lisa M. Nilsson, Jonas A. Nilsson
Format: Article
Language:English
Published: Nature Publishing Group 2021-08-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-021-25332-w

Internet

https://doi.org/10.1038/s41467-021-25332-w

Similar Items